Targeting IL4/IL4R for the Treatment of Epithelial Cancer Metastasis

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2015 Sep 20

PMID 26385103

Citations 57

Authors

Katherine Venmar Bankaitis

Barbara Fingleton

Affiliations

Soon will be listed here.

Abstract

While progress has been made in treating primary epithelial tumors, metastatic tumors remain largely incurable and still account for 85-90 % of all cancer-related deaths. Interleukin-4 (IL4), a Th2 cytokine, and the IL4/IL4 receptor (IL4R) interaction have well defined roles in the immune system. Yet, IL4 receptors are over-expressed by many epithelial cancers and could be a promising target for metastatic tumor therapy. The IL4/IL4R signaling axis is a strong promoter of pro-metastatic phenotypes in epithelial cancer cells including enhanced migration, invasion, survival, and proliferation. The promotion of breast cancer growth specifically is also supported in part by IL4-induced glutamine metabolism, and we have shown that IL4 is also capable of inducing glucose metabolism in breast cancer cells. Importantly, there are several types of FDA approved medications for use in asthma patients that inhibit the IL4/IL4R signaling axis. However, these approved medications inhibit both the type I IL4 receptor found on immune cells, and the type II IL4 receptor that is predominantly expressed by some non-hematopoietic cells including epithelial cancer cells. This article reviews existing therapies targeting IL4, IL4R, or IL4/IL4R signaling, and recent findings guiding the creation of novel therapies that specifically inhibit the type II IL4R, while taking into consideration effects on immune cells within the tumor microenvironment. Some of these therapies are currently in clinical trials for cancer patients, and may be exploitable for the treatment of metastatic disease.

Citing Articles

Adipocyte-derived CXCL10 in obesity promotes the migration and invasion of ovarian cancer cells.

Wang Z, Ou Q, Liu Y, Liu Y, Zhu Q, Feng J J Ovarian Res. 2024; 17(1):245.

PMID: 39702497 PMC: 11656578. DOI: 10.1186/s13048-024-01568-0.

Effects of Weizhuan'an on rats with precancerous lesions of gastric cancer based on regulating gastric mucosal microflora and inflammatory factors.

Lu Y, Liu H, Shang J, Mao Y, Meng L, Gao C Front Pharmacol. 2024; 15:1446244.

PMID: 39221149 PMC: 11361960. DOI: 10.3389/fphar.2024.1446244.

Integrated pan-cancer genomic analysis reveals the role of SLC30A5 in the proliferation, metastasis, and prognosis of hepatocellular carcinoma.

Liu Y, Lu T, Li R, Cui L, Xu R, Teng S J Cancer. 2024; 15(14):4686-4699.

PMID: 39006068 PMC: 11242337. DOI: 10.7150/jca.97214.

Integrated mRNA-miRNA transcriptome profiling of blood immune responses potentially related to pulmonary fibrosis in forest musk deer.

Qi W, Hu L, Gu Y, Zhang X, Jiang X, Li W Front Immunol. 2024; 15:1404108.

PMID: 38873601 PMC: 11169664. DOI: 10.3389/fimmu.2024.1404108.

HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer.

Ramos Solis N, Cannon A, Dilday T, Abt M, Oblak A, Soloff A Oncoimmunology. 2024; 13(1):2364382.

PMID: 38846083 PMC: 11155704. DOI: 10.1080/2162402X.2024.2364382.

References

Kuperman D, Schleimer R . Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med. 2008; 8(5):384-92. PMC: 4437630. DOI: 10.2174/156652408785161032. View

Hallett M, Venmar K, Fingleton B . Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012; 72(24):6338-43. PMC: 3531868. DOI: 10.1158/0008-5472.CAN-12-3544. View

Roca H, Craig M, Ying C, Varsos Z, Czarnieski P, Alva A . IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. J Cell Biochem. 2011; 113(5):1569-80. PMC: 3337359. DOI: 10.1002/jcb.24025. View

Andrews R, ROSA L, Daines M, Khurana Hershey G . Reconstitution of a functional human type II IL-4/IL-13 receptor in mouse B cells: demonstration of species specificity. J Immunol. 2001; 166(3):1716-22. DOI: 10.4049/jimmunol.166.3.1716. View

Mueller T, Zhang J, Sebald W, Duschl A . Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta. 2002; 1592(3):237-50. DOI: 10.1016/s0167-4889(02)00318-x. View

Umansky V, Sevko A . Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2012; 6(2):169-77. PMC: 3717060. DOI: 10.1007/s12307-012-0126-7. View

Gabitass R, Annels N, Stocken D, Pandha H, Middleton G . Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60(10):1419-30. PMC: 3176406. DOI: 10.1007/s00262-011-1028-0. View

Kemp R, Ronchese F . Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol. 2001; 167(11):6497-502. DOI: 10.4049/jimmunol.167.11.6497. View

Miklossy G, Hilliard T, Turkson J . Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013; 12(8):611-29. PMC: 4038293. DOI: 10.1038/nrd4088. View

10.

OHara J, Paul W . Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature. 1985; 315(6017):333-6. DOI: 10.1038/315333a0. View

11.

Leland P, Taguchi J, Husain S, Kreitman R, Pastan I, Puri R . Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med. 2000; 6(3):165-78. PMC: 1949945. View

12.

Leen A, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R . Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014; 22(6):1211-1220. PMC: 4048899. DOI: 10.1038/mt.2014.47. View

13.

Mattar T, Kochhar K, Bartlett R, Bremer E, Finnegan A . Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 1993; 334(2):161-4. DOI: 10.1016/0014-5793(93)81704-4. View

14.

Todaro M, Perez Alea M, Di Stefano A, Cammareri P, Vermeulen L, Iovino F . Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2008; 1(4):389-402. DOI: 10.1016/j.stem.2007.08.001. View

15.

Duppatla V, Gjorgjevikj M, Schmitz W, Hermanns H, Schafer C, Kottmair M . IL-4 analogues with site-specific chemical modification at position 121 inhibit IL-4 and IL-13 biological activities. Bioconjug Chem. 2013; 25(1):52-62. DOI: 10.1021/bc400307k. View

16.

Murata T, Noguchi P, Puri R . Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem. 1995; 270(51):30829-36. DOI: 10.1074/jbc.270.51.30829. View

17.

Friedman Ohana R, Kirkland T, Woodroofe C, Levin S, Uyeda H, Otto P . Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag. ACS Chem Biol. 2015; 10(10):2316-24. DOI: 10.1021/acschembio.5b00351. View

18.

Todaro M, Lombardo Y, Francipane M, Alea M, Cammareri P, Iovino F . Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008; 15(4):762-72. DOI: 10.1038/sj.cdd.4402305. View

19.

LaPorte S, Juo Z, Vaclavikova J, Colf L, Qi X, Heller N . Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008; 132(2):259-72. PMC: 2265076. DOI: 10.1016/j.cell.2007.12.030. View

20.

Li B, Yang X, Li P, Yuan Q, Liu X, Yuan J . IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. Biochem Biophys Res Commun. 2008; 369(2):554-60. DOI: 10.1016/j.bbrc.2008.02.052. View